Bicalutamide significantly improved OS in patient with locally advanced disease ( hazard ratios ( HR ) = 0.77 ( 95 % confidence interval ( CI ) : 0.63-0 .94 , p = 0.01 ) , regardless of baseline prostate-specific antigen ( PSA ) , with a survival benefit which was apparent throughout the study period .